Ревматические проявления сахарного диабета

В последние десятилетия наблюдается неуклонный рост распространенности сахарного диабета (СД) во всем мире, в том числе и в России. Большое внимание при СД традиционно уделяют микро- и макрососудистым осложнениям, однако при длительном и/или тяжелом течении СД возможно вовлечение и других органов, в том числе скелетно-мышечной системы и кожи. Поражение этих тканей при СД в большей степени объясняют избыточным образованием конечных продуктов гликирования. В статье рассмотрены основные ревматические проявления СД: синдром ограничения подвижности суставов, хироартропатия, контрактура Дюпюитрена, «щелкающий палец», адгезивный капсулит плечевого сустава, поражение ротаторной манжеты плеча, синдром карпального канала, нейроостеоартропатия Шарко, остеопороз, инфаркт мышцы, диабетическая склередема. Обсуждены вопросы патогенеза, диагностики и возможные методы терапии.

1. Дедов ИИ, Шестакова МВ, Майоров АЮ, редакторы. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 8-й выпуск. Сахарный диабет. 2017;20(1S):1-121 [Dedov II, Shestakova MV, Mayorov AYu, eds. Standards of specialized diabetes care. 8th ed. Sakharnyi Diabet = Diabetes Mellitus. 2017;20(1S):1-121 (In Russ.)]. doi: 10.14341/DM20171S8

2. Abate M, Schiavone C, Salini V, Andia I. Management of limited joint mobility in diabetic patients. Diabetes Metab Syndr Obes. 2013;6:197-207. doi: 10.2147/DMSO.S33943

3. Burner T, Gohr C, Mitton-Fitzgerald E, Rosenthal AK. Hyperglycemia reduces proteoglycan levels in tendons. Connect Tissue Res. 2012;53:535-41. doi: 10.3109/03008207.2012.710670

4. Abate M, Schiavone C, Pelotti P, Salini V. Limited joint mobility in diabetes and ageing: recent advances in pathogenesis and therapy. Int J Immunopathol Pharmacol. 2010;23(4):997-1003. doi: 10.1177/039463201002300404

5. Черников АА, Северина АС, Шамхалова МШ, Шестакова МВ. Роль механизмов «метаболической памяти» в развитии и прогрессировании сосудистых осложнений сахарного диабета. Сахарный диабет. 2017;20(2):126-34 [Chernikov AA, Severina AS, Shamkhalova MS, Shestakova MV. The role of «metabolic memory» mechanisms in the development and progression of vascular complications of diabetes mellitus. Sakharnyi Diabet = Diabetes Mellitus. 2017;20(2):126-34 (In Russ.)]. doi: 10.14341/7674

6. Franke S, Sommer M, Rü ster C, et al. Advanced glycation end products induce cell cycle arrest and proinflammatory changes in osteoarthritic fibroblast-like synovial cells. Arthritis Res Ther. 2009;11:R136. doi: 10.1186/ar2807

7. Sanguineti R, Puddu A, Mach F, et al. Advanced glycation end products play adverse proinflammatory activities in osteoporosis. Med Inflamm. 2014;2014:975872. doi: 10.1155/2014/975872

8. Kanazawa I. Interaction between bone and glucose metabolism. Endocr J. 2017;64:1043-53. doi: 10.1507/endocrj.EJ17-0323

9. Alikhani Z, Alikhani M, Boyd CM, et al. Advanced glycation end products enhance expression of pro-apoptotic genes and stimulate fibroblast apoptosis through cytoplasmic and mitochondrial pathways. J Biol Chem. 2005;280(13):12087-95. doi: 10.1074/jbc.M406313200

10. Shoji T, Koyama H, Morioka T, et al. Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Diabetes. 2006;55(8):2245-55. doi: 10.2337/db05-1375

11. Abate M, Schiavone C, Salini V. Neoangiogenesis is reduced in chronic tendinopathies of type 2 diabetic patients. Int J Immunopathol Pharmacol. 2012;25(3):757-61. doi: 10.1177/039463201202500322

12. Oliva F, Giai Via A, Maffulli N. Physiopathology of intratendinous calcific deposition. BMC Med. 2012;10:95. doi: 10.1186/1741-7015-10-95

13. Wang SH, Sun ZL, Guo YJ, et al. PPARgamma-mediated advanced glycation end products regulation of neural stem cells. Mol Cell Endocrinol. 2009;307:176-84. doi: 10.1016/j.mce.2009.02.012

14. Lebiedz-Odrobina D, Kay J. Rheumatic manifestations of diabetes mellitus. Rheum Dis Clin N Am. 2010;36:681-99. doi: 10.1016/j.rdc.2010.09.008

15. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010;316(2):129-39. doi: 10.1016/j.mce.2009.08.018

16. Larkin ME, Barnie A, Braffett BH, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Musculoskeletal complications in type 1 diabetes. Diabetes Care. 2014 Jul;37(7):1863-9. doi: 10.2337/dc13-2361

17. Gerrits EG, Landman GW, Nijenhuis-Rosien L, Bilo HJ. Limited joint mobility syndrome in diabetes mellitus: A minireview. World J Diabetes. 2015;6(9):1108-12. doi: 10.4239/wjd.v6.i9.1108

18. Ismail AA, Dasgupta B, Tanqueray AB, Hamblin JJ. Ultrasonographic features of diabetic cheiroarthropathy. Br J Rheumatol. 1996;35:676-9. doi: 10.1093/rheumatology/35.7.676

19. Khanna G, Ferguson P. MRI of diabetic cheiroarthropathy. AJR Am J Roentgenol. 2007;188(1):W94-5. doi: 10.2214/AJR.06.0672

20. Rosenbloom AL, Silverstein JH, Lezotte DC, et al. Limited joint mobility in childhood diabetes mellitus indicates increased risk for microvascular disease. N Engl J Med. 1981;305(4):191-4. doi: 10.1056/NEJM198107233050403

21. Al-Homood IA. Rheumatic conditions in patients with diabetes mellitus. Clin Rheumatol. 2013;32(5):527-33. doi: 10.1007/s10067-012-2144-8

22. Papanas N, Maltezos E. The diabetic hand: a forgotten complication? J Diabet Complicat. 2010;24(3):154-62. doi: 10.1016/j.jdiacomp. 2008.12.009

23. Hsu PC, Liao PY, Chang HH, et al. Nailfold capillary abnormalities are associated with type 2 diabetes progression and correlated with peripheral neuropathy. Medicine (Baltimore). 2016;95(52):e5714. doi: 10.1097/MD.0000000000005714

24. Banon S, Isenberg DA. Rheumatological manifestations occurring in patients with diabetes mellitus. Scand J Rheumatol. 2013;42(1):1-10. doi: 10.3109/03009742.2012.713983

25. Каратеев АЕ, Каратеев ДЕ, Орлова ЕС, Ермакова ЮА. «Малая» ревматология: несистемная ревматическая патология околосуставных мягких тканей верхней конечности. Часть 1. Современная ревматология. 2015;9(2):4-15 [Karateev AE, Karateev DE, Orlova ES, Ermakova YuA. Minor rheumatology: nonsystemic rheumatic disease of juxta-articular soft tissues of the upper extremity. Part 1. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(2):4-15 (In Russ.)]. doi: 10.14412/1996-7012-2015-2-4-15

26. Merashli M, Chowdhury TA, Jawad ASM. Musculoskeletal manifestations of diabetes mellitus. QJM. 2015;108(11):853-7. doi: 10.1093/qjmed/hcv106

27. Lui PPY. Tendinopathy in diabetes mellitus patients – Epidemiology, pathogenesis, and management. Scand J Med Sci Sports. 2017;27(8):776-87. doi: 10.1111/sms.12824

28. Papanas N, Courcoutsakis N, Papatheodorou K, et al. Achilles tendon volume in type 2 diabetic patients with or without peripheral neuropathy: MRI study. Exp Clin Endocrinol Diabetes. 2009;117(10):645-8. doi: 10.1055/s-0029-1224121

29. Batista F, Nery C, Pinzur M, et al. Achilles tendinopathy in diabetes mellitus. Foot Ankle Int. 2008;29(5):498-501. doi: 10.3113/FAI.2008.0498

30. Geoghegan JM, Clark DI, Bainbridge LC, et al. Risk factors in carpal tunnel syndrome. J Hand Surg Br. 2004;29(4):315-20. doi: 10.1016/j.jhsb.2004.02.009

31. Mader R, Lavi I. Diabetes mellitus and hypertension as risk factors for early diffuse idiopathic skeletal hyperostosis (DISH). Osteoarthritis Cartilage. 2009;17(6):825-8. doi: 10.1016/j.joca.2008.12.004

32. Chisholm KA, Gilchrist JM. The Charcot joint: a modern neurologic perspective. J Clin Neuromuscul Dis. 2011;13(1):1-13. doi: 10.1097/CND.0b013e3181c6f55b

33. Rajbhandari SM, Jenkins RC, Davies C, Tesfaye S. Charcot neuroarthropathy in diabetes mellitus. Diabetologia. 2002;45(8):1085-96. doi: 10.1007/s00125-002-0885-7

34. Sella EJ, Barrette C. Staging of Charcot neuroarthropathy along the medial column of the foot in the diabetic patient. J Foot Ankle Surg. 1999;38(1):34-40. doi: 10.1016/S1067-2516(99)80086-6

35. Ergen FB, Sanverdi SE, Oznur A. Charcot foot in diabetes and an update on imaging. Diabet Foot Ankle. 2013;4. doi: 10.3402/dfa.v4i0.21884. eCollection 2013.

36. Allo Miguel G, Garcia Fernandez E, Hawkins Carranza F. Diabetic Charcot neuroarthropathy of the knee in a patient with type-1 diabetes mellitus. Endocrine. 2015;49(3):863-4. doi: 10.1007/s12020-014-0466-9

37. Illgner U, van Netten J, Droste C, et al. Diabetic Charcot neuroarthropathy of the hand: clinical course, diagnosis, and treatment options. Diabetes Care. 2014;37(5):e91-2. doi: 10.2337/dc13-2903

38. Van Eeckhoudt S, Minet M, Lecouvet F, et al. Charcot spinal arthropathy in a diabetic patient. Acta Clin Belg. 2014;69(4):296-8. doi: 10.1179/2295333714Y.0000000031

39. Sellmeyer DE, Civitelli R, Hofbauer LC, et al. Skeletal Metabolism, Fracture Risk, and Fracture Outcomes in Type 1 and Type 2 Diabetes. Diabetes. 2016;65(7):1757-66. doi: 10.2337/db16-0063

40. Нуруллина ГМ, Ахмадуллина ГИ. Особенности костного метаболизма при сахарном диабете. Остеопороз и остеопатии. 2017;20(3):82-9 [Nurullina GM, Akhmadullina GI. Features of bone turnover in diabetes mellitus. Osteoporoz i Osteopatii = Osteoporosis and Bone Diseases. 2017;20(3):82-9 (In Russ.)]. doi: 10.14341/osteo2017382-89

41. Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia. 2005;48:1292-9. doi: 10.1007/s00125-005-1786-3

42. Janghorbani M, van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166:495-505. doi: 10.1093/aje/kwm106

43. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes – a metaanalysis. Osteoporos Int. 2007;18:427-44. doi: 10.1007/s00198-006-0253-4

44. Leidig-Bruckner G, Grobholz S, Bruckner T, et al. Prevalence and determinants of osteoporosis in patients with type 1 and type 2 diabetes mellitus. BMC Endocr Disord. 2014;14:33. doi: 10.1186/1472-6823-14-33

45. Oei L, Rivadeneira F, Zillikens MC, Oei EH. Diabetes, diabetic complications, and fracture risk. Curr Osteoporos Rep. 2015;13(2):106-15. doi: 10.1007/s11914-015-0260-5

46. Schwartz AV, Vittinghoff E, Bauer DC, et al.; Study of Osteoporotic Fractures (SOF) Research Group; Osteoporotic Fractures in Men (MrOS) Research Group; Health, Aging, and Body Composition (Health ABC) Research Group. Association of BMD and FRAX score with risk of fracture in older adults with

47. type 2 diabetes. JAMA. 2011;305(21):2184-92. doi: 10.1001/jama.2011.715

48. Hough FS, Pierroz DD, Cooper C, Ferrari SL; IOF CSA Bone and Diabetes Working Group. Mechanisms in endocrinology: Mechanisms and evaluation of bone fragility in type 1 diabetes mellitus. Eur J Endocrinol. 2016;174(4):R127-38. doi: 10.1530/EJE-15-0820

49. Mirza F, Canalis E. Secondary osteoporosis: pathophysiology and management. Eur J Endocrinol. 2015;173(3):R131-R151. doi: 10.1530/EJE-15-0118

50. Iyer SN, Drake AJ 3rd, West RL, Tanenberg RJ. Diabetic muscle infarction: a rare complication of long-standing and poorly controlled diabetes mellitus. Case Rep Med. 2011;2011:407921. doi: 10.1155/2011/407921

51. Horton WB, Taylor JS, Ragland TJ, et al. Diabetic muscle infarction: a systematic review. BMJ Open Diabetes Res Care. 2015;3:e000082. doi: 10.1136/bmjdrc-2015-000082

52. Arroyave JA, Aljure DC, Canas CA, et al. Diabetic muscle infarction: two cases: one with recurrent and bilateral lesions and one with usual unilateral involvement. J Clin Rheumatol. 2013;19(3):126-8. doi: 10.1097/RHU.0b013e318289edcb

53. Jawahar A, Balaji R. Magnetic resonance imaging of diabetic muscle infarction: report of two cases. Iowa Orthop J. 2014;34:74-7.

54. Murphy-Chutorian B, Han G, Cohen SR. Dermatologic manifestations of diabetes mellitus: a review. Endocrinol Metab Clin North Am. 2013;42(4):869-98. doi: 10.1016/j.ecl.2013.07.004

55. Martin C, Requena L, Manrique K, et al. Scleredema diabeticorum in a patient with type 2 diabetes mellitus. Case Rep Endocrinol. 2011;2011:560273. doi: 10.1155/2011/560273

56. Beers WH, Ince A, Moore TL. Scleredema adultorum of Buschke: a case report and review of the literature. Semin Arthritis Rheum. 2006;35(6):355-9. doi: 10.1016/j.semarthrit.2006.01.004

57. Tran K, Boyd KP, Robinson MR, Whitlow M. Scleredema diabeticorum. Dermatol Online J. 2013;19(12):20718.

58. Rongioletti F, Kaiser F, Cinotti E, et al. Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patients. J Eur Acad Dermatol Venereol. 2015;29(12):2399-404. doi: 10.1111/jdv.13272

59. Каратеев АЕ, Каратеев ДЕ, Ермакова ЮА. «Малая ревматология»: несистемная ревматическая патология околосуставных мягких тканей верхней конечности. Часть 2. Медикаментозные и немедикаментозные методы лечения. Современная ревматология. 2015;9(3):33-42 [Karateev AE, Karateev DE, Ermakova YuA. Minor rheumatology: nonsystemic rheumatic disease of juxta-articular soft tissues of the upper extremity. Part 2. Drug and non-drug treatments. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(3):33-42 (In Russ.)]. doi: 10.14412/1996-7012-2015-3-33-42

60. Kapur S, McKendry RJ. Treatment and outcomes of diabetic muscle infarction. J Clin Rheumatol. 2005;11(1):8-12. doi: 10.1097/01.rhu.0000152142.33358.f1

61. Dosenovic S, Jelicic Kadic A, Miljanovic M, et al. Interventions for neuropathic pain: an overview of systematic reviews. Anesth Analg. 2017;125(2):643-52. doi: 10.1213/ANE.0000000000001998

62. Alsaeedi SH, Lee P. Treatment of scleredema diabeticorum with tamoxifen. J Rheumatol. 2010;37(12):2636-7. doi: 10.3899/jrheum.100561

63. Kokpol C, Rajatanavin N, Rattanakemakorn P. Successful treatment of scleredema diabeticorum by combining local PUVA and colchicine: a case report. Case Rep Dermatol. 2012;4(3):265-8. doi: 10.1159/000345712

64. Gonnelli S, Caffarelli C, Giordano N, Nuti R. The prevention of fragility fractures in diabetic patients. Aging Clin Exp Res. 2015;27(2):115-24. doi: 10.1007/s40520-014-0258-3 64. Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. J Am Med Assoc. 2011;305:783-9. doi: 10.1001/jama.2011.190

65. Khamaisi M, Regev E, Yarom N, et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab. 2007;92(3):1172-5. doi: 10.1210/jc.2006-2036

66. Schwartz AV, Pavo I, Alam J, et al. Teriparatide in patients with osteoporosis and type 2 diabetes. Bone. 2016;91:152-8. doi: 10.1016/j.bone.2016.06.017

67. Naqvi A, Cuchacovich R, Saketkoo L, Espinoza LR. Acute Charcot arthropathy successfully treated with pamidronate: longterm follow-up. Am J Med Sci. 2008;335(2):145-8. doi: 10.1097/MAJ.0b013e3180a5e957

68. Thomsen NO, Cederlund RI, Andersson GS, et al. Carpal tunnel release in patients with diabetes: a 5-year follow-up with matched controls. J Hand Surg Am. 2014;39(4):713-20. doi: 10.1016/j.jhsa.2014.01.012

69. Cinar M, Akpinar S, Derincek A, et al. Comparison of arthroscopic capsular release in diabetic and idiopathic frozen shoulder patients. Arch Orthop Trauma Surg. 2010;130(3):401-6. doi: 10.1007/s00402-009-0900-2